This review will discuss the basic science behind CDK inhibitors, the seminal trials which led to the approval of these inhibitors in HR+/HER2− breast cancer, their use in the adjuvant setting as well as in HR+/HER2+ breast cancer, and the ongoing research to determine optimal sequencing and find predictive biomarkers. The gene discussed is ERBB2; the disease is breast cancer.